Defensive Valeant sets another investor-update conference; Perrigo again urges shareholders to reject Mylan bid;

@FiercePharma: Academic vets make strides in ongoing fight against deadly pig viruses. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Novo makes sure Denmark gets some of the action as it starts massive build up. Story | Follow @EricPFierce

@CarlyHFierce: Valeant board, Ackman back CEO Pearson as shares continue downward dive. More | Follow @CarlyHFierce

> Embattled Valeant Pharmaceuticals ($VRX) said it would host another conference call Tuesday morning, to update investors on its operations and its plans to shift from the controversial specialty pharmacy Philidor. Report

> Perrigo ($PRGO) urged shareholders to reject Mylan's ($MYL) hostile advances in a Monday letter, calling Mylan's governance shortfalls "legendary" and pointing out a new investigation by the Securities and Exchange Commission into a land deal involving one of its directors. Release

> India's Sun Pharmaceuticals saw sales slump in the third quarter, as Indian growth slowed and U.S. revenue plunged 28% on supply constraints stemming from trouble at its Halol plant in India. Report

> Valeant Pharmaceuticals' troubles hit several hedge funds' returns last month, Reuters reports, particularly Tiger Ratan, with 20% of its assets invested in Valeant shares, and Hound Partners, with a 15% investment. Report

> Spain's Almirall raised its outlook for the year on "strong operational performance" and a €20 million milestone payment from AstraZeneca ($AZN) after the launch of Duaklir in South Korea. Release

Medical Device News

@FierceMedDev: ICYMI: Dx Digest: Illumina launches $250M share repurchase program; Foundation Medicine stumbles with Q3 earnings miss. Article | Follow @FierceMedDev

@VarunSaxena2: The 11th commandment: Thou shall mention Botox in every article about Allergan. (Perhaps the deal is a ploy to increase its sales?!) | Follow @VarunSaxena2

@EmilyWFierce: Lilly, Merck join Valeant in DOJ spotlight with new inquiries on pricing. FiercePharma story | Follow @EmilyWFierce

> Medrobotics raises $25M to back FDA-cleared transoral surgical robotics system. News

> NIH, Medtronic-backed startup reports mixed Phase II deep brain stimulation data in Alzheimer's. Story

Biotech News

@FierceBiotech: FT: Amgen in the hunt for a $10B biotech buyout. Report | Follow @FierceBiotech

@JohnCFierce: So does anybody else think the FDA 's BTD program has run amuck? Teva's SD-809 is a BTD? Really? | Follow @JohnCFierce

@DamianFierce: Worried about a sophomore slump with this new $VRX album. More | Follow @DamianFierce

> Agios slips on mixed solid tumor data for its Celgene-partnered cancer drug. News

> Collegium's pain drug wins a 'tentative' FDA approval with Purdue blocking the way. Article

Animal Health News

> Schein outpaces Q3 earnings estimates but dampens full-year forecast. Item

> Academic vets make strides in ongoing fight against deadly pig viruses. More

> Sanofi explores 'strategic options' for Merial in bid to cut costs. Report

> Aratana misses Q3 sales targets, refocuses priorities on pain and appetite drugs. Story

> Trupanion coasts in Q3 with veterinary hospital push delivering sales. Article

Biotech IT News

> Transcriptic adds CRISPR gene editing to robotic lab. Story

> Cognizant lands IT deal with 100,000 Genomes Project. More

> Ex-trailblazer Knome accepts buyout bid from tiny Tute. Report

> SEC pursues trader over 'phony tweets' that sank Sarepta's stock. Story

> Flush with $90M in VC cash, Twist and Ginkgo strike massive synthetic DNA deal. Article

Pharma Marketing News

> Real-life insomnia stories at core of new Merck-backed awareness campaign. Article

> Are Takeda's 900 Contrave reps worth it? Maybe not, analyst says. More

> Lilly, Merck and Valeant feel sting of DOJ drug pricing probe. Report

> Want to win on pricing? Take a closer look at the numbers. Story

> Allergan pumps up its sales rep tally amid Viberzi launch, aesthetics push. Article

And Finally... Top companies are signing on to telemedicine to link their employees with cheap access to doctors. Report

Suggested Articles

Former Indivior CEO Shaun Thaxter will face six months in federal prison for his role in misleading government officials on the dangers of Suboxone.

As of Friday after local time, 36 people have died in Korea after getting flu shots provided by at least seven companies, including Sanofi.

Two prominent pneumococcal vaccines from Merck and Pfizer are running low in Europe in a possible ill omen for the coming winter: report.